CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 480 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02013180
NCT02013180N/ACompleted

Zinc/PSA Ratio as a Novel Biomarker for Prostate Cancer Detection

Bagcilar Training and Research Hospital·observational·Posted Dec 17, 2013·Updated Apr 16, 2019

In Brief

An observational study for Prostate Cancer Detection. Completed, enrolled 480 participants across 1 site.

Detailed Summary

Although Prostate Specific Antigen (PSA) is a useful marker for early detection of the prostate cancer, its specivity is not sufficient. Several PSA variations were defined in order to increase the specivity of the test, but they aren't much more effective than the PSA alone for detection of disease. In older studies reported that, serum and prostatic tissue zinc levels decreased in prostat cancer disease. In our study we aimed to establish the utility of serum zinc, PSA, free PSA/PSA (fPSA/tPSA), zinc/PSA, levels for early detection of the prostate cancer.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesTurkey (Türkiye)
Collaborators--

Timeline

N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedDec 17, 2013
Enrollment StartJul 1, 2012
Primary CompletionJan 1, 2013
Study CompletionJan 1, 2017
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 12.5 years ago